Vijaya Kumar, MD
Emergency Medicine · Detroit, MINPI 1306050786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by CSL Behring at 29.8% of the total. 2024 is the largest year on record at $42, 2.8 times the $15 reported in 2020.
Across 4 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$24
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21
- Pfizer$20
- Novartis$15
Across 41 payments — averaging $15,544 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$353K
- Novartis$199K
- E.r. Squibb & Sons, L.L.C.$81K
- Emergent Biosolutions Inc.$5K
What the payments were for
- Food & beverage$81100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Novartis | 1 | $15 |
How this compares
$81 in reported general payments places this provider in the 65th percentile of 2,532 emergency medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 28 | $160 |
| Naproxen | 28 | $108 |
| Famotidine | 35 | $94 |
| Dicyclomine Hcl | 12 | $69 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $61 |
| Cephalexin | 27 | $55 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Detroit
- Joseph MillerDetroit$202K
- Jacob ManteuffelDetroit$185K
- Phillip LevyDetroit$177K
- Robert WelchDetroit$44K
- Richard NowakDetroit$38K
- Kimberlydawn WisdomDetroit$37K
- James PaxtonDetroit$10K
- Ankit NanavatiDetroit$10K
- Tolulope SonuyiDetroit$6K
- Dion SamersonDetroit$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.